ConductScience.org, home

Trial · NCT00616330

Vaginal Infection Study

NCT00616330, Phase 3, Completed, Lumara Health, Inc.

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Vaginal Infection Study. Trials, record NCT00616330. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00616330

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Vaginal Infection Study
NCT number
NCT00616330
Status
Completed
Phases
Phase 3
Enrollment
1,443 participants, actual
Lead sponsor
Lumara Health, Inc.
Conditions
Vulvovaginitis, Vaginitis
Interventions
clindamycin phosphate/butoconazole nitrate, clindamycin phosphate, butoconazole nitrate
First posted
2008-02-15
Last updated
2012-03-05

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryClinical symptom resolution.baseline, 7 to 10 days and 21 to 30 days
SecondaryYeast Culture for Candidabaseline, 7 to 10 days and 21 to 30 daysNegative Yeast Culture for Candida result=response, Positive Yeast Culture for Candida result=no response
SecondaryGram stain Nugent scorebaseline, 7 to 10 days and 21 to 30 daysGram stain Nugent score of less than 4= resolution, Gram stain Nugent score of greater than 4= no resolution
SecondarySaline wet mount for clue cellsbaseline, 7 to 10 days and 21 to 30 daysSaline wet mount negative for clue cells=resolution, Saline wet mount positive for clue cells=no resolution

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00616330

GET https://conductscience.org/api/trials/v1/NCT00616330/registered